NRx Pharmaceuticals, Inc. Stock News

RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer

RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer,

News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.

They're risky. But with the high risk comes the potential for high rewards.

NRx is seeking to have the FDA grant its coronavirus treatment breakthrough designation, based on new, favorable data on the drug. NRXP stock is climbing on the news.

These penny stocks are on the move, early and here's why. The post Hot Penny Stocks To Watch Before Today's Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Investors are intrigued by the potential of the drugmaker's experimental coronavirus therapy.

With all eyes on the pandemic once again, these biotech players could be gaining more exposure.

The stock price of NRx Pharmaceuticals (NASDAQ: NRXP) increased by over 40% pre-market today. This is why it happened.

NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the CO

Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of Phase 2 vaccinated patients to assess the BriLife vaccine against the COVID-19 Delta variant. Bl

Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil. 

NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q3 2021 Results - Earnings Call Transcript

Conference Begins on November 15, 2021 Conference Begins on November 15, 2021

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has received the FDA's response to NRx's submission of updated manufacturing information for Zyesami (aviptadil). The completion of this review, without the i